| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CAREMAX Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 233,25 | -0,11 % | UnitedHealthcare führt KI-Assistenten "Avery" für Mitglieder ein | ||
| INTUITIVE SURGICAL | 403,90 | -0,63 % | Intuitive Surgical vs. Stryker: Which Surgical Tech Stock Leads? | ||
| THERMO FISHER | 422,75 | -0,39 % | EU genehmigt milliardenschwere Übernahme von Clario durch Thermo Fisher | DJ EU genehmigt milliardenschwere Übernahme von Clario durch Thermo Fisher
Von Edith Hancock
DOW JONES--Die Europäische Kommission hat die Übernahme des US-Medizintechnologie-Anbieters Clario... ► Artikel lesen | |
| ROKU | 80,88 | -1,62 % | Aurzen Official: Aurzen Announces Big Spring Sale for Aurzen Roku TV Smart Projectors | Designed to simplify both performance and usability, with a built-in Roku TV OS, Aurzen Roku TV Smart Projectors allow users to access thousands of streaming channels and apps instantly-without external... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,001 | -100,00 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update | SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| CENTENE | 28,005 | -1,04 % | Centene ernennt Theodore Pienkos zum neuen Chief Accounting Officer und Controller | ||
| QUIDELORTHO | 13,900 | -0,71 % | QuidelOrtho Corporation: Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer | SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment... ► Artikel lesen | |
| VERU | 2,295 | +0,22 % | Veru Inc.: Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | -- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 1,745 | 0,00 % | Tempest Therapeutics raises $2 million in private placement | ||
| NANO-X IMAGING | 2,290 | 0,00 % | Nano-X Imaging Ltd: Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina | Collaboration with Intec SRL drives commercial expansion of 3D medical imaging across a high-growth private healthcare market PETACH TIKVA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging... ► Artikel lesen | |
| FULGENT GENETICS | 14,600 | +1,39 % | Fulgent Genetics completes $56.9M pathology lab acquisitions | ||
| LANTHEUS | 65,98 | +0,83 % | Lantheus Holdings, Inc.: Lantheus Announces FDA Approval of PYLARIFY TruVu (piflufolastat F 18) Injection | New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 3,940 | +1,03 % | H.C. Wainwright raises Perspective Therapeutics price target to $13 | ||
| AMN HEALTHCARE SERVICES | 16,100 | +4,55 % | AMN Healthcare Services Inc: AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results | Quarterly revenue of $748 million- GAAP loss of ($0.20)/share and adjusted EPS of $0.22DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator... ► Artikel lesen |